U.K. cost watchdog rejects Roche, GSK cancer meds

The U.K. hasn't been kind to high-tech cancer drugs this week: The cost-effectiveness watchdog NICE rejected Roche's Herceptin and GlaxoSmithKline's Tykerb for use in breast cancer patients in combination with hormone-blocking drugs; and Roche's Avastin got stiff-armed as a treatment for colorectal cancer that has spread. Article | Report

Suggested Articles

An online pharmacy has again criticized FDA action after tipping off regulators to the existence of a dangerous impurity in Zantac and other antacids.

A group of senators is asking the FTC to take a careful look at pharma mergers given the cost of drugs in the U.S.

Life’s been tough for J&J's prostate cancer med Erleada in its battle with Pfizer-Astellas’ Xtandi. A new FDA nod could help level the playing field.…